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Phloroglucinol (P) and its methylated derivative (TMP) are both
phenol derivative antispasmodic agents (Fig. 1) acting on smooth
muscle and prescribed to treat acute spasmodic abdominal pain,
acute painful disorders of the urinary tract, and acute pain in gyne-
cology. It has been showed that P and TMP act by reducing glycerol-
induced abdominal pain and by inhibiting colonic phasic
contractions.1
Exceptionally, P and TMP are associated with muco-cutaneous
manifestations and allergic reactions. It has been reported, in the
French National pharmacovigilance database, 21 cases of anaphy-
laxis to phloroglucinol, including 16 cases of anaphylactic shock
and 5 cases of allergic skin reaction (unpublished data).
We report a case of anaphylaxis to phloroglucinol conﬁrmed by
skin testing.
Case report
We report the case of a 23 year old female patient, who has a
medical history of mildly active ulcerative colitis treated withFig. 1. From left to right, and up to down: phlorog
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The patient was evaluated in allergy consultation for a recent
generalized facial maculo-papular exanthema associated with
dysphonia, dysphagia and mild dyspnea that occurred 6 months
ago. In fact, this systemic reaction appeared half an hour after tak-
ing Spasfon®, paracetamol, loperamide and a cough syrup contain-
ing codeine (Polery®), during an inﬂuenza-like illness with
gastroenteritis. She then presented to the emergency department
where she was given intravenous H1 antihistamine plus a single
intravenous corticosteroid dose (methylprednisolone 1 mg/kg).
Dysphonia, dysphagia and dyspnea improved successfully and
she was discharged on oral antihistamine and corticosteroid for 5
days. The facial skin eruption disappeared slowly over 3e4 days.
All drugs that have been taken are known to cause allergic reac-
tions as side effects. Also, children and adult can commonly develop
urticaria as a result of viral respiratory infections.2
As this systemic reaction can evoke an immunological IgE medi-
ated mechanism, we decided to test all drugs that were taken on
that day. An allergic food reaction is unlikely, given the absence
of food intake for at least 6 h before the reaction, and the absence
of ingestion of unusual foods within the 24 h before the reaction.lucinol, trimebutine, mebeverine, pinaverium.
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Fig. 2. Intradermal test to Spasfon at concentration 1 mg/ml.
Letter to the Editor / Allergology International 65 (2016) 481e482482Since this reaction, paracetamol was reintroduced by the patient
without allergic symptoms and mesalamine (Pentasa®) was
continued on a daily based treatment with good tolerance. Skin
prick tests were initially done for Spasfon®, loperamide and
Polery®, and were strongly positive for Spasfon® and negative for
the others.
In fact, for skin prick testing, a 80 mg tablet of Spasfon® was
crushed in 1 ml of NaCl 0.9%, and turned out positive at 80 mg/
ml and 8 mg/ml. The skin tests were repeated by using the inject-
able solution of Spasfon® that only contains the active ingredient
phloroglucinol and NaCl. Prick tests were positive at 10 mg/ml
(with a mean weal diameter of 7 mm after 15 min compared to a
positive histamine control of 5 mm and a negative saline control
test). Intradermal tests at 10 mg/ml and 1 mg/ml were also positive
(with a mean initial wheal of 8 mm increasing to 40 mm 20 min
later surrounded by an erythema of 115 mm diameter at a skin
testing concentration of 1 mg/ml) (Fig. 2).
Single blinded challenge tests were performed for all the other
simultaneously ingested drugs and all turned out negative.
Thereby, skin tests and oral negative challenge tests, lead us to
conclude to an allergic reaction, IgE mediated, to trimethylphloro-
glucinol (Spasfon®) explaining the systemic reaction presented by
the patient.
From a pharmaco-chemical point of view, the TMPs is a phenol
derivative with antispasmodic properties that predisposes to cross
reactivity with other molecules such as paracetamol and other anti-
spasmodic such as pinaverium (Dicetel®), mebeverine (Spasmo-
priv® or Colopriv®) and trimebutine (Debridat®).
Given the past medical history of a chronic digestive disease
requiring frequent recourse to antispasmodics, ﬁnding a therapeu-
tic alternative was needed. We did an oral challenge test to trime-
butine, which was found to be negative.
Discussion
To our knowledge, no cases of documented immediate hyper-
sensitivity reactions to Spasfon® have been reported in the litera-
ture in full details. Only one, amongst a list of 333 drug inducedanaphylaxis from the French Allergy Vigilance Network.3 The only
information for this case is the positivity of skin prick test, as for
our patient.
In the case of our patient, the clinical history of facial skin erup-
tion, dyspnea, dysphonia and dysphagia, occurring 30 min after
drug intake, was compatible with an immediate, possibly IgE
dependent allergic reaction.
Due to the severity of the episode, skin and oral challenge tests
were done for all possible drugs involved. Prick test to Spasfon®was
the only positive test at a concentration of 80 mg/ml and 8 mg/ml.
Since no standardized dosage is known for skin testing to this drug,
ten healthy controls were tested and were all negative. We vali-
dated the positivity for the active ingredient, and not the excipients,
by carrying out prick tests using the injectable solution.
A total of twenty-one cases of anaphylaxis, out of which 16 with
anaphylactic shock, following ingestion of Spasfon® have been
declared to the French National Pharmacovigilance Database. Al-
lergy work-up was performed only in 2 cases, including our patient,
and the patient declared to the French Allergy Vigilance Network,3
both had a positive prick test to Spasfon® (unpublished data).
Although exceptional, allergic reactions to phloroglucinol and
trimethylphloroglucinol need to be conﬁrmed or inﬁrmed when-
ever they were part of the therapeutic arsenal. The multiple avail-
able drugs with “benzene ring” in their chemical structure
require searching for possible cross reactivity with other similar
products.
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